The effects of Celebrex on mammary tumorigenesis and aging in HER2/neu transgenic mice

It is well known that cyclooxygenase-2 (COX2) plays an important role in the development of many tumors including breast cancer. Our study was concerned with evaluating the effects of the selective COX2 inhibitor, celecoxib, on mammary tumorigenesis and aging in HER2/neu transgenic mice (24). Celecoxib (celebrex) 25 mg/kg was administered 5 times a week from the age of 2 months. Twenty-four intact females were in control. Monitoring kept track of tumor detection time, size, presence of lung metastases, food and water consumption, estral function, body weight and temperature. No significant differences between the two groups were reported as far as life-span, tumor growth rate, size and number of metastases to the lung is concerned. To sum up, celecoxib treatment failed to produce any significant effect on carcinogenesis in HER2/neu transgenic mice.